Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo

Seyoung S Lee, Megan A Evans, Hannah X Chu, H Hyun Ah Kim, Robert E Widdop, Grant R Drummond, Christopher G Sobey

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Functional modulation of the non-AT1R arm of the renin-angiotensin system, such as via AT2R activation, is known to improve stroke outcome. However, the relevance of the Mas receptor, which along with the AT2R forms the protective arm of the renin-angiotensin system, as a target in stroke is unclear. Here we tested the efficacy of a selective MasR agonist, AVE0991, in in vitro and in vivo models of ischemic stroke. Primary cortical neurons were cultured from E15-17 mouse embryos for 7-9 d, subjected to glucose deprivation for 24 h alone or with test drugs, and percentage cell death was determined using trypan blue exclusion assay. Additionally, adult male mice were subjected to 1 h middle cerebral artery occlusion and were administered either vehicle or AVE0991 (20 mg/kg i.p.) at the commencement of 23 h reperfusion. Some animals were also treated with the MasR antagonist, A779 (80 mg/kg i.p.) 1 h prior to surgery. Twenty-four h after MCAo, neurological deficits, locomotor activity and motor coordination were assessed in vivo, and infarct and edema volumes estimated from brain sections. Following glucose deprivation, application of AVE0991 (10-8 M to 10-6 M) reduced neuronal cell death by 60 (P
Original languageEnglish
Article numbere0142087
Number of pages11
JournalPLoS ONE
Volume10
Issue number11
DOIs
Publication statusPublished - 2015

Cite this

@article{95370f12b113412e951f5d56880d556d,
title = "Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo",
abstract = "Functional modulation of the non-AT1R arm of the renin-angiotensin system, such as via AT2R activation, is known to improve stroke outcome. However, the relevance of the Mas receptor, which along with the AT2R forms the protective arm of the renin-angiotensin system, as a target in stroke is unclear. Here we tested the efficacy of a selective MasR agonist, AVE0991, in in vitro and in vivo models of ischemic stroke. Primary cortical neurons were cultured from E15-17 mouse embryos for 7-9 d, subjected to glucose deprivation for 24 h alone or with test drugs, and percentage cell death was determined using trypan blue exclusion assay. Additionally, adult male mice were subjected to 1 h middle cerebral artery occlusion and were administered either vehicle or AVE0991 (20 mg/kg i.p.) at the commencement of 23 h reperfusion. Some animals were also treated with the MasR antagonist, A779 (80 mg/kg i.p.) 1 h prior to surgery. Twenty-four h after MCAo, neurological deficits, locomotor activity and motor coordination were assessed in vivo, and infarct and edema volumes estimated from brain sections. Following glucose deprivation, application of AVE0991 (10-8 M to 10-6 M) reduced neuronal cell death by 60 (P",
author = "Lee, {Seyoung S} and Evans, {Megan A} and Chu, {Hannah X} and Kim, {H Hyun Ah} and Widdop, {Robert E} and Drummond, {Grant R} and Sobey, {Christopher G}",
year = "2015",
doi = "10.1371/journal.pone.0142087",
language = "English",
volume = "10",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo. / Lee, Seyoung S; Evans, Megan A; Chu, Hannah X; Kim, H Hyun Ah; Widdop, Robert E; Drummond, Grant R; Sobey, Christopher G.

In: PLoS ONE, Vol. 10, No. 11, e0142087, 2015.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo

AU - Lee, Seyoung S

AU - Evans, Megan A

AU - Chu, Hannah X

AU - Kim, H Hyun Ah

AU - Widdop, Robert E

AU - Drummond, Grant R

AU - Sobey, Christopher G

PY - 2015

Y1 - 2015

N2 - Functional modulation of the non-AT1R arm of the renin-angiotensin system, such as via AT2R activation, is known to improve stroke outcome. However, the relevance of the Mas receptor, which along with the AT2R forms the protective arm of the renin-angiotensin system, as a target in stroke is unclear. Here we tested the efficacy of a selective MasR agonist, AVE0991, in in vitro and in vivo models of ischemic stroke. Primary cortical neurons were cultured from E15-17 mouse embryos for 7-9 d, subjected to glucose deprivation for 24 h alone or with test drugs, and percentage cell death was determined using trypan blue exclusion assay. Additionally, adult male mice were subjected to 1 h middle cerebral artery occlusion and were administered either vehicle or AVE0991 (20 mg/kg i.p.) at the commencement of 23 h reperfusion. Some animals were also treated with the MasR antagonist, A779 (80 mg/kg i.p.) 1 h prior to surgery. Twenty-four h after MCAo, neurological deficits, locomotor activity and motor coordination were assessed in vivo, and infarct and edema volumes estimated from brain sections. Following glucose deprivation, application of AVE0991 (10-8 M to 10-6 M) reduced neuronal cell death by 60 (P

AB - Functional modulation of the non-AT1R arm of the renin-angiotensin system, such as via AT2R activation, is known to improve stroke outcome. However, the relevance of the Mas receptor, which along with the AT2R forms the protective arm of the renin-angiotensin system, as a target in stroke is unclear. Here we tested the efficacy of a selective MasR agonist, AVE0991, in in vitro and in vivo models of ischemic stroke. Primary cortical neurons were cultured from E15-17 mouse embryos for 7-9 d, subjected to glucose deprivation for 24 h alone or with test drugs, and percentage cell death was determined using trypan blue exclusion assay. Additionally, adult male mice were subjected to 1 h middle cerebral artery occlusion and were administered either vehicle or AVE0991 (20 mg/kg i.p.) at the commencement of 23 h reperfusion. Some animals were also treated with the MasR antagonist, A779 (80 mg/kg i.p.) 1 h prior to surgery. Twenty-four h after MCAo, neurological deficits, locomotor activity and motor coordination were assessed in vivo, and infarct and edema volumes estimated from brain sections. Following glucose deprivation, application of AVE0991 (10-8 M to 10-6 M) reduced neuronal cell death by 60 (P

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634944/pdf/pone.0142087.pdf

U2 - 10.1371/journal.pone.0142087

DO - 10.1371/journal.pone.0142087

M3 - Article

VL - 10

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 11

M1 - e0142087

ER -